The PCTM, which has been running in the US since 2016, measures and tracks the usage of pan-cancer tests, which are designed to test for a wide range of cancer types to help doctors make more informed treatment decisions.
The study gathers perceptions from medical oncologists and pathologists on topics such as awareness and current utilisation of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. In addition, it incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test. The detailed information collected includes: brand used, reason for testing, reasons for brand choice, treatment impact, test outcome, satisfaction with test, and more. Further expansion of the study to Asia-Pacific markets is planned for the coming months.
Commented Pieter De Richter, Head of Syndicated Real World Evidence in APAC/MENA for Ipsos Healthcare: “Pan-cancer testing is a rapidly growing, continually evolving and extremely dynamic market segment. While the US has been leading the charge when it comes to the adoption of innovative Next Generation Sequencing panels for anti-cancer treatment selection, the APAC region represents a huge opportunity for the adoption of these panels. With the launch of the study in Australia, we are now able to provide molecular diagnostics businesses and pharma companies with robust insights into drivers and barriers around the usage of pan-cancer testing panels and detailed usage metrics within this important region.”
Exporting healthcare: a new phase for the ‘lucky country’
Australia’s economy is in transition. The nation is actively trying to set course for an economy where the relative GDP footprint earned from being the world’s quarry is smaller, replaced all manner of services, knowledge and experiences; mostly exported into emerging Asian countries. We are plotting a plan to be less brawn, more brains. Less soil, more skills.